Replimune Awaits FDA Decision on RP1 Melanoma Therapy by April 10
Replimune Group Inc. approaches a critical regulatory milestone as the FDA is scheduled to decide on its RP1 melanoma therapy by April 10, 2026, with cash reserves extending into early 2027.
The U.S. Food and Drug Administration is scheduled to issue its decision on the Biologics License Application for RP1 by April 10, 2026, the Prescription Drug User Fee Act target date. The therapy is designed for use in combination with nivolumab to treat patients with advanced melanoma.
The FDA's prior acceptance of the resubmitted application brought the potential commercialization of RP1 one step closer. This upcoming decision represents the definitive threshold between the company's clinical development phase and its potential entry into the market.
Replimune Group Inc.'s financial results for the third fiscal quarter of 2026 exceeded analyst consensus estimates for earnings per share. Management has confirmed that existing cash and equivalents are sufficient to fund operations into the first quarter of 2027.
This substantial liquidity buffer affords the leadership team significant flexibility. It allows the company to navigate the upcoming regulatory review process without the immediate pressure to seek additional capital.
While the April decision on RP1 for melanoma is the primary near-term catalyst, Replimune's broader development pipeline remains a key component of its valuation. Additional clinical data readouts for RP1 in other cancer indications, alongside progress for the candidate RP2, are anticipated throughout the remainder of the calendar year.
The publication of the subsequent quarterly earnings report is currently scheduled for the period between May 15 and May 22, 2026.